MapLight Therapeutics Q4 EPS $(2.47) Misses $(0.96) Estimate

MapLight Therapeutics (NASDAQ: MPLT) reported a Q4 loss of $(2.47) per share, significantly missing the analyst consensus estimate of $(0.96) by 156.49%. This loss represents a 91.16% increase compared to losses of $(27.95) per share from the same period last year.